Kamada Ltd. (NASDAQ:KMDA) released its earnings results on Tuesday, August 1st. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.01, MarketWatch Earnings reports. Kamada had a negative return on equity of 2.94% and a negative net margin of 2.24%. The firm had revenue of $32.55 million for the quarter, compared to the consensus estimate of $33.30 million. During the same period in the prior year, the firm earned ($0.04) EPS. The firm’s revenue was up 70.7% on a year-over-year basis.
Shares of Kamada (KMDA) opened at 4.30 on Friday. Kamada has a 12-month low of $3.75 and a 12-month high of $8.61. The stock’s market capitalization is $160.82 million. The firm has a 50-day moving average of $5.15 and a 200 day moving average of $6.56.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://stocknewstimes.com/2017/08/19/kamada-ltd-kmda-posts-quarterly-earnings-results-beats-estimates-by-0-01-eps-updated-updated.html.
A number of hedge funds and other institutional investors have recently bought and sold shares of KMDA. Edmond DE Rothschild Holding S.A. raised its position in Kamada by 10.5% in the second quarter. Edmond DE Rothschild Holding S.A. now owns 42,200 shares of the biotechnology company’s stock worth $251,000 after buying an additional 4,000 shares in the last quarter. Norges Bank purchased a new stake in shares of Kamada during the fourth quarter valued at $377,000. Acadian Asset Management LLC purchased a new stake in shares of Kamada during the first quarter valued at $575,000. Renaissance Technologies LLC increased its stake in shares of Kamada by 20.4% in the fourth quarter. Renaissance Technologies LLC now owns 227,000 shares of the biotechnology company’s stock valued at $1,237,000 after buying an additional 38,500 shares during the last quarter. Finally, Nexthera Capital LP purchased a new stake in shares of Kamada during the second quarter valued at $1,805,000. Institutional investors own 5.73% of the company’s stock.
Several research firms recently issued reports on KMDA. Jefferies Group LLC reissued a “buy” rating and issued a $9.00 target price on shares of Kamada in a research report on Wednesday, May 17th. Zacks Investment Research downgraded Kamada from a “hold” rating to a “sell” rating in a research report on Tuesday, July 18th. Finally, TheStreet downgraded Kamada from a “c-” rating to a “d+” rating in a research report on Tuesday, August 1st.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.
